You are here: Industry Insights > AstraZeneca

News List

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
AstraZeneca revenues soar with nearly $4bn in Covid-19 vaccine sales Pharmaceutical-Technology
February 11, 2022
The drugmaker, which is just beginning to profit from its Covid-19 vaccine, has recorded $37.4bn in revenue.
AstraZeneca reports 41% growth in FY 2021 total revenue Pharmaceutical-Technology
February 11, 2022
Total revenue for the Covid-19 sector was recorded at $4.11bn in FY 2021.
AstraZeneca-Daiichi Sankyo’s breast cancer therapy gets FDA priority review Pharmaceutical-Technology
January 19, 2022
The sBLA is based on results from the international, open-label Phase III DESTINY-Breast03 trial of Enhertu.
New AstraZeneca treatment for rare cancer reduces risk of death pharmatimes
January 19, 2022
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
BenevolentAI and AstraZeneca expand drug discovery partnership Pharmaceutical-Technology
January 17, 2022
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
AstraZeneca welcomes US government’s announcement to purchase additional 500,000 doses of Evusheld ExpressPharma
January 14, 2022
Evusheld has Emergency Use Authorisation (EUA) for pre-exposure prophylaxis (prevention) of COVID-19.
New Vaxzevria data further support its use as third dose booster WorldPharmaNews
January 14, 2022
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster...
AstraZeneca, Ovid Therapeutics Partner Against Epilepsy contractpharma
January 03, 2022
Transaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines.
AstraZeneca, Ionis close deal on antisense therapy development pharmaceutical-business-review
December 30, 2021
under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page